It is now well established that KRAS mutations are the main reason for resistance to anti-epidermal growth factor receptor (EGFR) antibodies [7,8], and account for nearly two-thirds of EGFR downstream effector alterations in colorectal cancer [9]. Here, KRAS is linked to colorectal cancer.